Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007

Clinical Lymphoma and Myeloma

Volumn 7, Issue SUPPL. 3, 2007, Pages

  Mughal, Tariq ^a   Goldman, John M ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Abl kinase inhibitors; Abl Src kinase inhibitor; Bcr AblT315I mutation; Combination therapy

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; 5 AZA 2' DEOXYCYTIDINE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; BCR ABL PROTEIN; BORTEZOMIB; BOSUTINIB; COLONY STIMULATING FACTOR 1; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; ELASTASE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; INNO 406; LONAFARNIB; MYELOBLASTIN; NILOTINIB; NS 187; PEGINTERFERON ALPHA; RAPAMYCIN; TIPIFARNIB; UNCLASSIFIED DRUG; WORTMANNIN; PROTEIN KINASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE PAIN; BRAIN EDEMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; DRUG WITHDRAWAL; EDEMA; ENZYME ACTIVITY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HEART MUSCLE INJURY; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MYELODYSPLASIA; MYOCARDIAL DISEASE; NAUSEA; NEUTROPENIA; NONHUMAN; PERICARDIAL EFFUSION; PLEURA EFFUSION; PROTEIN EXPRESSION; PRURITUS; RASH; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; CHEMISTRY; CHILD; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; HISTORY; METABOLISM; PRESCHOOL CHILD; REVIEW; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HISTORY, 21ST CENTURY; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PROTEIN KINASE INHIBITORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 34249694651     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.s.008     Document Type: Article

References (54)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290.
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96:3343-3356.
3. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of the BCR-ABL positive cells. Nat Med 2000; 2:561.
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
5. Mughal TI, Goldman JM. Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era. Front Biosci 2006; 1:209-220.
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 2006; 355:2408-2417.
7. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-α based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108:1835-1840.
8. Mughal TI, Yong A, Szydlo R, et al. The probability of long-term leukaemia free survival for patients in molecular remission 5 years after allogeneic stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol 2001; 115:569-574.
9. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromsome positive leukemias. N Engl J Med 2006; 354:2531-2541.
10. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant Philadelphia chromsome-positive leukemias. N Engl J Med 2006; 354:2542-2551.
11. Mahon F-X, Huguet F, Etienne G, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission: an update follow up. Blood 2006; 108:61 1a (Abstract #2154).
12. Aoki E, Kantarjian H, O'Brien S, et al. High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5 year follow-up. J Clin Oncol 2006; 24:18s (Abstract #6535).
13. Ebonether M, Stentoft J, Ford J, et al. Cerebral edema as a possible complication of treatment with imatinib. Lancet 2002; 359:1751-1752.
14. Strebhardt K, Ullrich A. Another look at imatinib mesylate. N Engl J Med 2006; 355:2481-2482.
15. Kerakela R, Grazette L, Yacobi R, etal. Cardiotoxicity of the cancer therapeutic agent imatib mesylate. Nat Med 2006; 12:908-916.
16. Attallah FT, Kantarjian H, Cortes J, et al. In reply to "cardiotoxicity of the cancer therapeutic agent imatinib mesylate." Nat Med 2007; 2:224.
17. Hatfield A, Owen S, Pilot PR. In reply to 'cardiotoxicity of the cancer therapeutic agent imatib mesylate.' Nat Med 2007; 2:224.
18. Kovitz C, Kantarjian H, Garcia-Manero G, et al. Myelodysplasia syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108:2811-2813.
19. Griffin JD. Resistance to targeted therapy in leukaemia. Lancet 2002; 359:458-459.
20. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105:2640-2653.
21. Guilhot F. Mutation detection in CML: is it a useful tool? Blood 2005; 106:1897-1898.
22. Baccarani M, Saglio G, Goldman JM, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108:1809-1820.
23. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28-37.
24. Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 2005; 23:6316-6324.
25. Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 2004; 104:4245-4251.
26. Issa J-P, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23:3948-3956.
27. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003; 101:1692-1697.
28. Cortes J, O'Brien S, Verstovsek S, et al. Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients (pts) with chronic myeloid leukemia (CML) after failure to imatinib. Blood 2004; 104:288a (Abstract #1009).
29. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86:3322-3326.
30. Mughal TI. Dasatinib, a novel Abl-Src kinase inhibitor, in the management of patients with Philadelphia chromosome-positive leukemias. Clin Leuk 2006; 1:15-18.
31. Copland N, Hamilton A, Elrick L, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107:4532-4539.
32. Baccarani M, Kantarjian H, Apperley JA, et al. Efficacy of dasatinib (Sprycel) in patients with chronic phase chronic myeloid leukaemia resistant to or intolerant of imatinib: updated results of CA180013 "START-C" phase II study. Blood 2006; 108:53a (Abstract #164).
33. Cortes J, O'Brien S, Jones D, et al. Dasatinib (Sprycel) in patients with previously untreated chronic myelogenous leukaemia in chronic phase. Blood 2006; 108:613a (Abstract #2161).
34. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukaemia after failure of imatinib therapy. Blood 2006 [Epub ahead of print].
35. Qunitas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chrnic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007; 109:497-499.
36. Hocchaus A, Kim DW Rousselot R et al. Dasatinib (Sprycel) 50mg or 70mg BID versus 110mg or 140mg QD in patients with chronic myeloid leukemia in chronic phase resistant or intolerant to imatinib : results of the CA180-034 study. Blood 2006; 108:53a (Abstract #166).
37. Cortes J, O'Brien S, Jones D, et al. Dasatinib (Srycel) in patients with previously untreated chronic myeloid leukemia in chronic phase. Blood 2006; 108:613a (Abstract #2161).
38. Quintas-Cardama A, Kantarjian HM, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007; 109:497-499.
39. Mughal TI. Nilotinib in the post-imatinib era for the treatment of Philadelphia chromosome positive leukemias. Clin Leuk 2006; 1:84-86.
40. Jabbour E, Giles F, Cortes J, et al. Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome(Ph)-positive chronic phase chronic myelogenous leukemia. J Clin Oncol 2006; 24(18 suppl):358s (Abstract #6591).
41. Srivastava PK. Immunotherapy of human cancer: lessons from mice. Nat Immunol 2000; 1:363-366.
42. Rojas JM, Knight K, Wang L, et al. The immune response to BCR-ABL peptide immunization is variable and transient in chronic myeloid leukaemia: results from the EPIC study. Haematologica 2006; 1(suppl):177 (Abstract #27).
43. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6:1018-1023.
44. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365:657-659.
45. Zeng Y, Graner MW, Thompson S, et al. Induction of BCR-ABL-specific immunity following vaccination with chaperone rich lysates from BCR-ABL+ tumor cells. Blood 2005; 105:2016-2022.
46. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WFI (Wilms tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101:13885-13890.
47. Cortes J, Kantarjian H, Baccarani M, et al. A phase1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 2006; 108:54a (Abstract #168).
48. Tao W, Sun T, Craig A, et al. The ATP competitor INNO-406 (NS-187) inhibits proliferation and survival of mouse cells expressing several imatinib mesylate resistant Bcr/Abl mutants and cells from CML patients. Blood 2006; 108:618a (Abstract #2179).
49. Rao R, Fiskus W, Herger B, et al. Inhibition of histone deactylase (HDAC) 6 and/or heat shock protein (HSP) 90: a strategy to abrogate multi-level protective responses to misfolded proteins induced by proteasome inhibitors in human leukemia cells. Blood 2006, 108:80a (Abstract #257).
50. Wolff NC, Veach DR, Tong WP, et al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myelogenous leukemia. Blood 2005; 105:3995-4003.
51. Giles FR, Cortes J, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia with the T3151 BCR-ABL mutation. Blood 2007; 109:500-502.
52. Carter BZ, Mak DH, Schober WD, et al. Regulation of surviving expression through Bcr-Abl/MAPK cascade: targeting surviving overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 2006; 107:1555-1563.
53. Deininger M, Schleuning M, Greinix H, et al. The effects of prior exposure to imatinib on transplant related mortality. Haematologica 2006; 91:452-459.
54. Oehler V, Gooley T, Snyder D, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109:1782-1789.